Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StemCell InstituteTSE:7096 -2.40%69 PS Ratio is 2.63 as of Jul. 21, 2026, which is 74% below its 10-year median of 10.04. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,818.02 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, StemCell Institute ranks better than 78.71% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, StemCell Institute's share price is 円731.00.
StemCell Institute's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円278.39. Hence, StemCell Institute's PS Ratio for today is 2.63.
The historical rank and industry rank for StemCell Institute's PS Ratio or its related term are showing as below:
TSE:7096'
s PS Ratio Range Over the Past 10 Years
Min: 2.35 Med: 10.04 Max: 23.65
Current: 2.63
During the past 9 years, StemCell Institute's highest PS Ratio was 23.65. The lowest was 2.35. And the median was 10.04.
TSE:7096's PS Ratio is ranked better than 78.71% of 930
companies
in the Biotechnology industry
Industry Median: 9.3
vs TSE:7096: 2.63
StemCell Institute revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of StemCell Institute was 6.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 10.90% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 14.10% per year.
During the past 9 years, StemCell Institute's highest 3-Year average Revenue per Share Growth Rate was 19.90% per year. The lowest was 7.60% per year. And the median was 15.15% per year.
Back to Basics: PS Ratio
StemCell Institute (TSE:7096) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
StemCell Institute PS Ratio Related Terms
StemCell Institute PS Ratio Historical Data
* Premium members only.
The historical data trend for StemCell Institute's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, StemCell Institute's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's PS Ratio distribution charts can be found below:
* The bar in red indicates where StemCell Institute's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
StemCell Institute's Share Price of today is 円731.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. StemCell Institute's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円278.39.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
StemCell Institute (TSE:7096) has a PS Ratio of 2.63 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on StemCell Institute and its competitors. This is 74% below median its historical median of 10.04. Over the past decade, StemCell Institute's PS Ratio has ranged from 2.35 to 23.65. According to the industry distribution chart, StemCell Institute ranks #198 out of 930 companies in the Biotechnology industry, placing it in the top 21.3%.
Is StemCell Institute's PS Ratio too high?
StemCell Institute's current PS Ratio of 2.63 is 74% below median its 10-year median of 10.04. Over the past 10 years, this metric has ranged from a low of 2.35 to a high of 23.65. The Biotechnology industry median PS Ratio is 9.30. StemCell Institute's value of 2.63 is 71.7% below this industry median. Based on the distribution chart, StemCell Institute ranks #198 out of 930 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #198 out of 930 companies for PS Ratio. This places StemCell Institute in the top 21% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.30. StemCell Institute's value of 2.63 is 71.7% below this benchmark. Historically, StemCell Institute's own PS Ratio has ranged from 2.35 to 23.65 over the past decade. While the company's 10-year median is 10.04 vs. the industry median of 9.30, StemCell Institute has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.30, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. StemCell Institute's current PS Ratio of 2.63 is 71.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on StemCell Institute and its competitors. For the Biotechnology industry, the median PS Ratio is 9.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. StemCell Institute's current PS Ratio is 2.63, which is 74% below median its own 10-year median of 10.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,818.02, compared to a current price of 円731.00 — trading 59.8% below its estimated fair value. The current PS Ratio is 2.63, which is 74% below median its 10-year median of 10.04 and 71.7% below the Biotechnology industry median of 9.30. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current PS Ratio is 2.63 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円731.00 is trading 59.8% below its estimated GF Value™ of 円1,818.02.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
PS Ratio: 2.63 (74% below median its 10-year median of 10.04)
GF Value™: 円1,818.02 vs. price of 円731.00 (59.8% below fair value)
Industry Position: 71.7% below the Biotechnology median (#198 of 930)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
